Abstract 94P
Background
Thirty percent of patients with early-stage NSCLC are treated without a pathological diagnosis. With upcoming neoadjuvant immuno- and targeted therapies it is important to complete a molecular diagnosis before treatment. Bronchoalveolar lavage fluid (BALF) is easily collected and minimal invasive but has poor diagnostical yield in standard cytological work-up. A potential new diagnostic tool could be detection of circulating tumor DNA (ctDNA), in which genetic and epigenetic alterations of the tumor can be detected. The aim of this study is to determine if cell free (cfDNA) analysis in BALF is representative for the molecular diagnosis in NSCLC.
Methods
49 BALF samples of patients with suspected NSCLC have been analyzed. During the routine bronchoscopy or EBUS, bronchoalveolar lavage was performed in the affected lobe and usual material for routine diagnostics was obtained. Samples were analyzed using the Oncomine PAN-Cancer Cell-free NGS panel and the molecular results were compared.
Results
Analysis has been done on 53 patients. In 42 patients a molecular alteration was found. In 79% of the cases the cfDNA analysis of the BALF was completely or partly representative. In 12 patients a molecular alteration was found in BALF while this was not found with a regular endoscopy (bronchoscopy and or EBUS). After more diagnostics (eg CT guided biopsy) 18 patients did not have a cyto-or histopathological molecular result pretreatment, 6 of those had a positive BALF cfDNA result. BALF analysis reduced the number of patients in this cohort without a pretreatment molecular diagnosis by a third.
Conclusions
In conclusion, cfDNA from BALF as a source for molecular diagnostics is highly comparable with routine diagnostic material and could reduce the number of patients treated without a molecular diagnosis. Furthermore, BALF is easily obtained, and the procedure is relatively minimal invasive. In 10 cases the only pathogenic variant found in BALF is a TP53 mutation. When only a TP53 mutation is found, no hard conclusions can be drawn regarding the origin of the tumor and thus the diagnosis NSCLC, since TP53 is also often found in other malignancies. As long as this is considered, BALF could be an additional diagnostic tool for patients with NSCLC.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The author.
Funding
Team Westland.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract